PMID- 34845162
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220824
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 33
IP  - 3
DP  - 2022 Mar 1
TI  - Circ_0005033 is an oncogene in laryngeal squamous cell carcinoma and regulates 
      cell progression and Cisplatin sensitivity via miR-107/IGF1R axis.
PG  - 245-256
LID - 10.1097/CAD.0000000000001260 [doi]
AB  - Transcriptome expression profiles of laryngeal squamous cell carcinoma (LSCC) are 
      altered, and we aimed to investigate expression and role of hsa_circ_0005033 
      (circ_0005033), microRNA (miR)-107 and insulin-like growth factor 1 receptor 
      (IGF1R) in LSCC. Real-time PCR, western blotting and immunohistochemistry 
      detected RNA and protein expression levels. Functional assays were performed 
      using MTT assay, EdU assay, apoptosis assay, flow cytometry, Transwell assay, and 
      xenograft tumor model. Direct interaction was predicted by Starbase algorithm and 
      validated by dual-luciferase reporter assay and RNA immunoprecipitation. 
      Expression of circ_0005033 was substantially upregulated in LSCC tissues and 
      cells, and allied with miR-107 downregulation and IGF1R upregulation. 
      Circ_0005033 showed a closed-loop structure and long half-life. Essentially, 
      circ_0005033 and IGF1R were competing endogenous RNAs for miR-107 via target 
      binding. Silencing circ_0005033 facilitated apoptosis rate and lowered cell 
      viability, proliferation, migration and invasion of LSCC cells, as well as 
      delayed xenograft tumor growth. Allied with that, cleaved-caspase 3/8/9 
      expression was elevated via death receptor-mediated and mitochondrial pathways, 
      and expression of matrix metalloproteinase-2 (MMP2), MMP9, cyclin D1 and 
      proliferating cell nuclear antigen was decreased. Moreover, Cisplatin-induced 
      inhibition of cell viability was exacerbated by inhibiting circ_0005033. These 
      functional effects of circ_0005033 depression were consistent with those of 
      miR-107 overexpression. Furthermore, depleting miR-107 and restoring IGF1R abated 
      the effects of circ_0005033 knockdown and miR-107 overexpression, respectively. 
      Circ_0005033 was oncogenic in LSCC by regulating cell progression and Cisplatin 
      sensitivity at least via miR-107/IGF1R axis.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Gong, Lei
AU  - Gong L
AD  - Department of Otolaryngology, Affiliated Hospital of Shandong Medical College, 
      Qingdao.
FAU - Chen, Juan
AU  - Chen J
AD  - Department of Otolaryngology, Affiliated Hospital of Shandong Medical College, 
      Qingdao.
FAU - Jiang, Xijiao
AU  - Jiang X
AD  - Department of Otolaryngology, The First People's Hospital of Jiangxia District of 
      Wuhan, Union Jiangnan Hospital, Wuhan, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
RN  - 0 (IGF1R protein, human)
RN  - 0 (MIRN107 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Cell Proliferation
MH  - Cisplatin/pharmacology
MH  - *Head and Neck Neoplasms/genetics
MH  - Humans
MH  - Matrix Metalloproteinase 2/genetics
MH  - *MicroRNAs/genetics/metabolism
MH  - Oncogenes
MH  - RNA, Circular/genetics
MH  - Receptor, IGF Type 1/genetics
MH  - Squamous Cell Carcinoma of Head and Neck/drug therapy/genetics
EDAT- 2021/12/01 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/11/30 06:11
PHST- 2021/12/01 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2021/11/30 06:11 [entrez]
AID - 00001813-202203000-00003 [pii]
AID - 10.1097/CAD.0000000000001260 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2022 Mar 1;33(3):245-256. doi: 10.1097/CAD.0000000000001260.